Kishan Amar U, Wang Pin-Chieh, Sheng Ke, Yu Victoria, Ruan Dan, Cao Minsong, Tenn Stephen, Low Daniel A, Lee Percy
Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
Technol Cancer Res Treat. 2015 Aug;14(4):411-8. doi: 10.1177/1533034614551476. Epub 2014 Sep 26.
Radiographic changes occur in over half of patients treated with stereotactic body radiotherapy (SBRT) to the lung, correlating histopathologically with injury. We quantified radiographic density changes (ie, fibrosis) at 3, 6, and 12 months and investigated the relationship between these volumes and clinical and dosimetric parameters. The study population consisted of patients treated with SBRT to the lung for stage I primary lung cancers (n = 39) or oligometastatic lesions (n = 17). Fractionation schemes included 3 fractions of 12, 14, or 18 gray (Gy) and 4 fractions of 12 or 12.5 Gy prescribed to cover 95% of the planning target volume (PTV). Planning computed tomography (CT) scans were rigidly registered to follow-up CT scans obtained at intervals of 3, 6, and 12 months. Fibrotic volumes were contoured on the follow-up scans. Associations between the volume of fibrosis and clinical and dosimetric parameters were investigated using univariate linear regression. Scans were available for 65 and 47 lesions at 6 and 12 months, respectively. Age, years since quitting smoking, and GOLD Global Initiative for Chronic Obstructive Lung Disease score were significantly associated with increasing volume of fibrosis (P < .05). Total dose, dose per fraction, PTV, and volumetric parameters (V0-V55) were also significantly associated with increasing volumes of fibrosis (P < .01). For dosimetric parameters, the effect was largest for V55. Age, significant smoking history, and GOLD score were significantly associated with increasing volumes of fibrosis following SBRT. In a multivariate model adjusted for age and smoking history, V10 through V50 and PTV size remained significant predictors of fibrotic volume. Further, there is a strong dose-response relationship between the volume of lung exposed to a certain dose and the fibrotic volume. The predominant kinetic patterns of fibrosis demonstrate peaking fibrotic volumes at 6 and 12 months. These results provide insight for expectations of fibrosis after SBRT.
接受立体定向体部放疗(SBRT)治疗的肺癌患者中,超过半数会出现影像学改变,其在组织病理学上与损伤相关。我们对3个月、6个月和12个月时的影像学密度变化(即纤维化)进行了量化,并研究了这些体积与临床和剂量学参数之间的关系。研究人群包括接受SBRT治疗I期原发性肺癌(n = 39)或寡转移病灶(n = 17)的患者。分割方案包括12、14或18格雷(Gy)的3次分割以及12或12.5 Gy的4次分割,规定剂量覆盖计划靶体积(PTV)的95%。将计划计算机断层扫描(CT)与间隔3个月、6个月和12个月获得的随访CT进行刚性配准。在随访扫描上勾勒出纤维化体积。使用单变量线性回归研究纤维化体积与临床和剂量学参数之间的关联。分别有65个和47个病灶在6个月和12个月时可获得扫描图像。年龄、戒烟年限和慢性阻塞性肺疾病全球倡议(GOLD)评分与纤维化体积增加显著相关(P < 0.05)。总剂量、分次剂量、PTV和体积参数(V0 - V55)也与纤维化体积增加显著相关(P < 0.01)。对于剂量学参数,V55的影响最大。年龄、显著吸烟史和GOLD评分与SBRT后纤维化体积增加显著相关。在根据年龄和吸烟史调整的多变量模型中,V10至V50以及PTV大小仍然是纤维化体积的显著预测因子。此外,暴露于特定剂量的肺体积与纤维化体积之间存在强烈的剂量反应关系。纤维化的主要动力学模式显示在6个月和12个月时纤维化体积达到峰值。这些结果为SBRT后纤维化的预期提供了见解。